Is there a future for prenyltransferase inhibitors in cancer therapy?

► N-Ras and K-Ras resistant to FTIs as a consequence of alternative geranylgeranylation. ► Minimal clinical activity of FTIs in phase I-III trials. ► RASGRP1/APTX-gene expression as predictor of response to tipifarnib in AML.